 |
Chelation TherapyThere are two types of these therapies, IV and Oral Chelation. These procedures require a high degree of knowledge about the process and chemicals used in the process, so any type of chelation should be done under the supervision of licensed doctors. If administered in a wrong manner, this procedure and chemicals involved can be dangerous to the patient. Also, it has been advised that before embarking on oral or IV chelation treatment, accurate determination of the degree of minerals and toxic element presence in the body should be carried out. IV chelation usually uses a solution mixed with magnesium bound EDTA, which s a chemical that is widely used as a food preservative (and therefore generally recognized as safe). It has been suggested in research that EDTA chelates heavy metal from the vascular wall, kidney and brain. EDTA has been shown in research to bind to toxic metals such as lead, free iron, cadmium, and it has been suggested, to a lesser extent, arsenic and mercury. In a study conducted by Walter Blumer, M.D., published in Journal of Advancement in Medicine (Volume 2, Numbers 1/2, Spring/Summer 1989), mortality from cancer in research subjects was reduced 90% in comparison to control group during an 18-year follow-up of 59 patients treated with an IV push of calcium EDTA. It is important to note that treated patients had no evidence of cancer at the time of entry into this study, which raises interesting possibilities of chelation as a cancer prevention tool for further research. As for oral chelation, this form of therapy has also shown beneficial effects in research, though less potently than the IV form. There are various forms of EDTA available in oral form, most commonly magnesium- or calcium-bound EDTA. Most researchers suggest that chelation treatment must be supplemented with a high potency, anti-oxidant and mineral, formula which adequately protects against chromium deficiency. Chelation Therapy - StudiesWalter Blumer. and Elmer M. Cranton. Ninety Percent Reduction in Cancer Mortality After Chelation Therapy with EDTA. Journal of Advancement in Medicine, Volume 2, Numbers 1/2, Spring/Summer 1989. Foreman, EI., and Trujillo, T. T.: The Metabolism of C14 Labedled Ethylenediaminetetraacetic Acid in Human Beings, J. Lab. & Clin. Med. 43:566-571 (April) 1954. Sidbury, J. B., Jr.: Bynum, J. C.; and Fetz, L. L.: Effect of Chelating Agent on Urinary Lead Excretion: Comparison of Oral and Intravenous Administration, Proc. Soc. Exper. Biol. & Med. 82:226, 1953. Cotter, L. H.: Treatment of Lead Poisoning by Chelation, J.A.M.A.155:906-908 (July 3) 1954. Shiels, D. O.; Thomas, D. L. G.; and Kearley, E.: Treatment of Lead Poisoning by Edathamil Calcium Disodium, A.M.A. Arch. Indust. Health 13:489-498 (May) 1956. Pagnotto, L.D.; Elkins, H. B.: and Bayka, I.: Oral Administration of Edathamil Calcium Disodium (Calcium Disodium Versenate), A.M.A. Arch. Indust. Health 17:29-33 (Jan.) 1958. Bell, R. F.; Gilliland, J. C.: Boland, J. R.; and Sullivan, B. R.: Effect of Oral Edathamil Calcium Disodium on Urinary and Fecal Lead Excretion, A.M.A. Arch. Indust. Health 13:366-371. (April) 1956. Manville, I. A., and Moser, R.: Recent Developments in the Care of Workers Exposed to Lead, A.M.A. Arch. Indust. Health 12:528-538 (Nov.) 1955.
|